Huang Guo-Liang, Lu Yan, Pu Xing-Xiang, He Yu-Xiang, Chen Mei-Ling, Li Ya-Zhen, Tang Shu-Yin, Che Hua, He Zhiwei
Sino-American Cancer Research Institute, Guangdong Medical College, Dongguan, Guangdong 523808, P.R. China ; Key Laboratory for Medical Molecular Diagnostics of Guangdong, Dongguan, Guangdong 523808, P.R. China.
Department of Medical Oncology, Hunan Tumor Hospital, Changsha, Hunan 410006, P.R. China.
Biomed Rep. 2013 Jul;1(4):599-603. doi: 10.3892/br.2013.97. Epub 2013 Apr 23.
Association studies between single-nucleotide polymorphism (SNP) rs2292832 on miR-149 gene and cancer risk have been previously analyzed in several types of cancer. The aim of this study was to evaluate the association between miR-149 polymorphism and risk of nasopharyngeal carcinoma (NPC). miR-149 gene polymorphism was genotyped using polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) in 158 patients with NPC and 242 healthy individuals. Associations with cancer risk and clinicopathological characteristics were analyzed by χ test. No significant difference was observed for miR-149 gene polymorphism in NPC patients and healthy controls in either genotype (P=0.427 for CC vs. CT vs. TT, P=0.247 for CT vs. TT and P=0.323 for CC vs. TT, respectively) or allelic analysis (P=0.216). No significant difference was noted between the genotypes and the clinicopathological parameters examined with the exception of clinical stage. A significantly higher CC distribution in clinical stage I-II compared with III-IV was observed under the dominant model (CC vs. CT vs. TT, P=0.026) and the co-dominant model (CC vs. TT, P=0.030). The results of this study suggested that the CC genotype of miR-149 contributes to the progression and development, rather than the initiation of NPC.
此前已针对多种癌症类型分析了miR - 149基因上的单核苷酸多态性(SNP)rs2292832与癌症风险之间的关联研究。本研究旨在评估miR - 149多态性与鼻咽癌(NPC)风险之间的关联。采用聚合酶链反应(PCR)-限制性片段长度多态性(RFLP)方法对158例NPC患者和242例健康个体进行miR - 149基因多态性基因分型。通过χ检验分析与癌症风险及临床病理特征的关联。在NPC患者和健康对照中,miR - 149基因多态性在基因型分析(CC与CT与TT相比,P = 0.427;CT与TT相比,P = 0.247;CC与TT相比,P = 0.323)或等位基因分析(P = 0.216)中均未观察到显著差异。除临床分期外,基因型与所检查的临床病理参数之间未发现显著差异。在显性模型(CC与CT与TT,P = 0.026)和共显性模型(CC与TT,P = 0.030)下,观察到临床I - II期的CC分布显著高于III - IV期。本研究结果表明,miR - 149的CC基因型促进了NPC的进展和发展,而非其起始。